CN111195235A - Method for hydrating cyclophosphamide freeze-dried composition and product thereof - Google Patents

Method for hydrating cyclophosphamide freeze-dried composition and product thereof Download PDF

Info

Publication number
CN111195235A
CN111195235A CN201811367499.4A CN201811367499A CN111195235A CN 111195235 A CN111195235 A CN 111195235A CN 201811367499 A CN201811367499 A CN 201811367499A CN 111195235 A CN111195235 A CN 111195235A
Authority
CN
China
Prior art keywords
composition
cyclophosphamide
lyophilized
hydrated
cpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811367499.4A
Other languages
Chinese (zh)
Inventor
俞洪珍
李自强
万建胜
盛小茜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SINOTHERAPEUTICS Inc
Original Assignee
SINOTHERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SINOTHERAPEUTICS Inc filed Critical SINOTHERAPEUTICS Inc
Priority to CN201811367499.4A priority Critical patent/CN111195235A/en
Priority to US17/265,678 priority patent/US20220133754A1/en
Priority to EP19844577.7A priority patent/EP3831366A4/en
Priority to PCT/CN2019/099251 priority patent/WO2020025069A1/en
Priority to CN201980051898.6A priority patent/CN112533591A/en
Priority to PCT/IB2019/059802 priority patent/WO2020100088A1/en
Priority to US16/684,038 priority patent/US20200155579A1/en
Publication of CN111195235A publication Critical patent/CN111195235A/en
Priority to IL283170A priority patent/IL283170A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

The present invention relates to a method for hydrating a lyophilized cyclophosphamide composition and to the hydrated product obtained by said method.

Description

Method for hydrating cyclophosphamide freeze-dried composition and product thereof
Technical Field
The invention relates to the field of pharmaceutical preparations, in particular to a hydration method of a cyclophosphamide freeze-dried composition and a product thereof.
Background
In the field of pharmaceutical formulation, the stability of a pharmaceutically active ingredient is a very important consideration. The stability of pharmaceutical formulations is often affected by various factors, including moisture content. For many pharmaceutical active ingredients and pharmaceutical preparations thereof, the moisture content is not as low as possible, but rather a certain range is required. In the case of Cyclophosphamide (CPP), there are various hydrates or forms without hydrates. Among these, the anhydrate is very unstable when exposed to conditions of above 25 ℃ or low relative humidity. However, when exposed to an environment having a relative humidity of 20-30% RH or higher, the anhydrous hydrate gradually absorbs water to form a monohydrate. While the monohydrate is in a stable form, in a dry environment (e.g., relative humidity below about 20%), the monohydrate may begin to lose water of crystallization. Therefore, cyclophosphamide is not very stable, and maintaining a certain moisture content is essential to maintain the stability of the pharmaceutically active ingredient. Furthermore, in the commercial production process, it is very difficult to maintain the crystalline water content in all the CPPs in the freeze-dried bottles to be uniform by controlling the freeze-drying process, which causes some commercial production problems.
US 4,537,883 and US 5,413,995 disclose various CPP lyophilized products, after a solution containing CPP and auxiliary materials is lyophilized, the lyophilized composition is hydrated, wherein the hydration method comprises 1) after the completion of the freeze drying, sterile air and/or nitrogen with the relative humidity of 80% is introduced into a lyophilization chamber under the condition of normal pressure and room temperature to obtain the CPP lyophilized products with the moisture content within a certain range; or 2) introducing sterile water vapor into the freeze-drying chamber under the condition of reduced pressure and room temperature to obtain the CPP freeze-dried product with the water content within a certain range.
US 4,659,699 discloses a two-step process for the preparation of a CPP lyophilized product, wherein the hydration process comprises: spraying sufficient water vapor into the lyophilization chamber using a nozzle such that the relative humidity of the lyophilization chamber is greater than 75%; the water vapor is continuously sprayed for 5min-2h, so that the relative humidity of the freeze-drying chamber is kept about 85% until the freeze-drying composition absorbs enough water, and therefore the CPP freeze-dried product with a certain water content is obtained.
However, none of the above methods are suitable for commercial production. For example, the introduction of sterile air/nitrogen at a certain humidity into the lyophilization chamber, the preparation of sterile air/nitrogen at a certain humidity is difficult, the relative humidity of the lyophilization chamber is not easy to control and it is difficult to ensure the sterility of the entire process. Since CPP is a product for injection, the need for sterility is not insignificant. Or a certain calculated amount of hot water vapor is introduced into the freeze-drying chamber in a short time while maintaining a high vacuum degree, the method is complicated in calculation, and the preparation and introduction of the hot water vapor are difficult. In addition, because the water vapor is easy to generate supersaturation, water drops are easy to generate around the freeze-dried penicillin bottle or in the freeze-dried box, so that the freeze-dried composition is polluted, and the hydration of the freeze-dried composition is not uniform.
Therefore, there is a need to develop a hydration method of a lyophilized composition containing a pharmaceutically active ingredient such as cyclophosphamide which overcomes the drawbacks of the prior art to obtain a lyophilized product which is stable and suitable for commercial production.
Disclosure of Invention
In one aspect, the invention relates to a method of hydrating a lyophilized cyclophosphamide composition, comprising:
(a) providing an aqueous solution containing cyclophosphamide and optionally pharmaceutically acceptable excipients;
(b) freeze-drying the solution to obtain a lyophilized composition; and
(c) hydrating the lyophilized composition with liquid water, thereby obtaining a hydrated cyclophosphamide lyophilized composition.
In one embodiment, the cyclophosphamide in step (a) is in the form of a hydrate, an anhydrate or a mixture thereof, preferably cyclophosphamide monohydrate.
In another embodiment, the moisture content of the lyophilized composition obtained in step (b) is not higher than about 5%, preferably not higher than about 4%, more preferably not higher than about 3%, most preferably not higher than about 2%, relative to the weight of the lyophilized composition.
In one embodiment, the liquid water used in step (c) is in the form of pure water or an aqueous solution.
In yet another embodiment, the aqueous solution in step (c) is preferably an aqueous solution having a relative humidity value of 40-100% RH at room temperature. Examples thereof may be an aqueous solution containing one or more selected from strong acids, strong bases, glycerin, inorganic salts, and pharmaceutically acceptable adjuvants, and preferably an aqueous solution containing glycerin or an inorganic salt.
In a preferred embodiment, the aqueous solution containing a strong acid is an aqueous solution containing sulfuric acid.
In a preferred embodiment, the aqueous solution containing a strong base is an aqueous solution containing potassium hydroxide or sodium hydroxide.
In a preferred embodiment, the concentration of glycerol in the glycerol-containing aqueous solution may be adjusted according to the desired relative humidity, and may be present in a range of 0 to 100 wt.%, based on the total weight of the aqueous solution, for example, may be a concentration of 10 wt.%, 20 wt.%, 30 wt.%, 35 wt.%, 40 wt.%, 45 wt.%, 50 wt.%, 55 wt.%, 60 wt.%, 70 wt.%, 80 wt.%, 90 wt.%, or 100 wt.%. Preferably 20 to 60 wt%, more preferably 30 to 50 wt%.
In a preferred embodiment, the aqueous solution containing an inorganic salt is an aqueous solution containing one or more of a sodium salt, a potassium salt, a lithium salt, a magnesium salt, a calcium salt, an ammonium salt, a cesium salt, a cobalt salt, and a strontium salt containing an anion, preferably an aqueous solution containing one or more of cesium fluoride, lithium bromide, zinc bromide, lithium chloride, calcium bromide, lithium iodide, potassium acetate, potassium fluoride, magnesium chloride, sodium iodide, potassium carbonate, potassium nitrate, sodium bromide, cobalt chloride, potassium iodide, strontium chloride, sodium nitrate, sodium chloride, ammonium chloride, potassium bromide, ammonium sulfate, potassium chloride, strontium nitrate, potassium sulfate, potassium chromate, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium citrate, and potassium citrate, more preferably an aqueous solution containing one or more of cesium fluoride, lithium bromide, lithium chloride, potassium acetate, potassium fluoride, potassium citrate, and more preferably an aqueous solution containing one or more of cesium fluoride, lithium, An aqueous solution of one or more of magnesium chloride, potassium carbonate, sodium bromide, potassium iodide, sodium chloride, potassium chloride and potassium sulfate. In a preferred embodiment, the concentration of the inorganic salt in the aqueous solution containing the inorganic salt may be adjusted according to the desired relative humidity, and may be a concentration of 0 to 100% saturation, for example, a concentration of 5% saturation, 10% saturation, 20% saturation, 30% saturation, 40% saturation, 50% saturation, 60% saturation, 70% saturation, 80% saturation, 90% saturation or 100% saturation.
In a preferred embodiment, the aqueous solution containing pharmaceutically acceptable excipients is an aqueous solution containing one or more selected from sugars, organic solvents and surfactants.
In a preferred embodiment of the above aspect, the hydrated lyophilized cyclophosphamide composition obtained in step (c) has a moisture content of about 2-7%, preferably about 3-6%, more preferably about 3.7-5.5% relative to the weight of the hydrated lyophilized cyclophosphamide composition. In an alternative embodiment, the hydrated lyophilized cyclophosphamide composition obtained in step (c) has a moisture content of about 4-12%, preferably about 5-10%, more preferably about 6-9% relative to the weight of cyclophosphamide monohydrate.
In another aspect, the present invention also relates to a hydrated lyophilized cyclophosphamide composition obtained by the hydration method of the present invention.
In one embodiment, the moisture content of the hydrated composition is from about 2% to about 7%, preferably from about 3% to about 6%, more preferably from about 3.7% to about 5.5%, by weight of the hydrated composition. In an alternative embodiment, the hydrated lyophilized cyclophosphamide composition has a moisture content of about 4-12%, preferably about 5-10%, more preferably about 6-9% based on the weight of cyclophosphamide monohydrate.
Drawings
FIG. 1 depicts the superimposed XRD patterns of β -mannitol, delta-mannitol, CPP monohydrate, and hydrated CPP lyophilized compositions prepared by the examples of the present invention.
FIG. 2 is an XRD pattern of a crystalline form of a CPP lyophilized composition hydrated with pure water.
FIG. 3 is an XRD pattern of a CPP lyophilized composition hydrated with sodium chloride solution.
FIG. 4 is an XRD pattern of a CPP lyophilized composition hydrated with glycerol solution.
Detailed Description
The invention will be described in further detail below with the understanding that the terminology is intended to be in the nature of words of description rather than of limitation.
Definition of
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present application will control. When an amount, concentration, or other value or parameter is expressed in terms of a range, preferred range, or upper preferable numerical value and lower preferable numerical value, it is understood that any range defined by any pair of upper range limits or preferred numerical values in combination with any lower range limits or preferred numerical values is specifically disclosed, regardless of whether the range is specifically disclosed. Unless otherwise indicated, numerical ranges set forth herein are intended to include the endpoints of the ranges and all integers and fractions (decimal) within the range.
While various measurements may be made using the machines or processes described herein, it should be noted that the measurements are not limited to only those machines or processes described. It is contemplated that other machines or programs may be used to obtain these measurements.
The terms "about" and "approximately," when used in conjunction with a numerical variable, generally mean that the value of the variable and all values of the variable are within experimental error (e.g., within 95% confidence interval for the mean) or within ± 10% of the specified value, or more.
The terms "optional" or "optionally present" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
The expressions "comprising" or similar expressions "including", "containing" and "having" and the like which are synonymous are open-ended and do not exclude additional, unrecited elements, steps or components. The expression "consisting of …" excludes any element, step or ingredient not specified. The expression "consisting essentially of …" means that the scope is limited to the specified elements, steps or components, plus optional elements, steps or components that do not materially affect the basic and novel characteristics of the claimed subject matter. It is to be understood that the expression "comprising" covers the expressions "consisting essentially of …" and "consisting of …".
The term "one or more" or "at least one" may mean one, two, three, four, five, six, seven, eight, nine or more.
The terms "pharmaceutically active ingredient", "therapeutic agent", "active substance" or "active agent" refer to a chemical entity that is effective in treating or preventing a disease or disorder of interest. The pharmaceutically active ingredient used in the method of the present invention is not particularly limited, but is particularly suitable for active ingredients that are present in the form of a lyophilized product and have strict requirements on the range of moisture content. In one embodiment, the pharmaceutically active ingredient is cyclophosphamide.
Cyclophosphamide is a bifunctional nitrogen mustard alkylating agent and a cell cycle non-specific drug, can interfere functions of DNA and RNA, is clinically used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like, and can also be used for treating rheumatoid arthritis, children nephrotic syndrome and autoimmune diseases.
Figure BDA0001868970780000041
The nitrogen mustard compound is unstable in aqueous solution and easy to degrade. Therefore, the currently marketed or under-developed CPP products are mainly sterile powders for injection prepared by the freeze-drying method.
The term "cyclophosphamide monohydrate" refers to the monohydrate of cyclophosphamide, of formula C7H15Cl2N2O2P·H2And O. The moisture content of CPP monohydrate can be determined, for example, using USP 40-NF 35Method I<921>Karl-Fischer (Karl-Fischer) direct titration as described in (1). The term "cyclophosphamide anhydrous" refers to the anhydrous form of CPP of formula C7H15Cl2N2O2And P. In one embodiment of the invention, the cyclophosphamide used may be in the form of a hydrate (e.g. monohydrate), an anhydrate or a mixture thereof, preferably a monohydrate.
Without intending to be bound by theory, the term "cyclophosphamide impurity a" as used herein and in accordance with the united states pharmacopeia refers to a specific cyclophosphamide related compound or related chemical having the chemical name bis (2-chloroethyl) amine hydrochloride and the structural formula of formula (II):
Figure BDA0001868970780000042
without intending to be bound by theory, the term "cyclophosphamide impurity B" as used herein and in accordance with the united states pharmacopeia refers to a specific cyclophosphamide related compound or related chemical having the chemical name 3- (2-chloroethyl) -2-oxo-2-hydroxy-1, 3,6, 2-oxadiazolphosphine, or 3- (2-chloroethyl) octahydro-2-hydroxy-1, 3,6, 2-oxadiazolphosphine 2-oxide and structural formula (III):
Figure BDA0001868970780000051
without intending to be bound by theory, the term "cyclophosphamide impurity D" as used herein and in accordance with the united states pharmacopeia refers to the specific cyclophosphamide related compounds or related chemicals having the chemical name 3- [ [2- [ (2-chloroethyl) amino ] ethyl ] amino ] propyl monophosphate dihydrochloride and the structural formula of formula (IV):
Figure BDA0001868970780000052
the term "lyophilized pharmaceutical composition" or "lyophilized composition" refers to a composition in lyophilized form obtained after lyophilization of an aqueous solution containing a pharmaceutically active ingredient and optionally pharmaceutically acceptable excipients. When cyclophosphamide is used as the active ingredient, such a lyophilized composition may also be referred to as a lyophilized cyclophosphamide composition or a lyophilized cyclophosphamide composition.
Accordingly, the terms "hydrated lyophilized (drug) composition", "hydrated product" refer to a composition or product obtained by hydrating a lyophilized form of a (drug) composition by the method of the invention. In one embodiment, the active ingredient is cyclophosphamide.
When calculating the moisture content in the lyophilized composition or the hydrated composition, cyclophosphamide is taken as an example, since the raw material used is generally cyclophosphamide monohydrate, in calculating the moisture content in the lyophilized composition or the hydrated composition, cyclophosphamide monohydrate is generally used as a base. In this case, whether cyclophosphamide is present in the form of a monohydrate, an anhydrate or a mixture thereof, the anhydrate or other forms that may be present are converted to cyclophosphamide monohydrate. Alternatively, the moisture content in a composition or product may also be calculated based on the weight of the composition or product.
For example, in one embodiment, the moisture content in the lyophilized composition is not greater than about 9%, preferably not greater than about 7%, more preferably not greater than about 5.5%, and most preferably not greater than about 3.5% relative to the weight of cyclophosphamide monohydrate.
In an alternative embodiment, the moisture content of the lyophilized composition is not greater than about 5%, preferably not greater than about 4%, more preferably not greater than about 3%, and most preferably not greater than about 2% by weight of the lyophilized composition.
In another embodiment, the moisture content of the hydrated composition is about 4-12%, preferably about 5-10%, more preferably about 6-9%, more preferably about 6.5-9.0% relative to the weight of cyclophosphamide monohydrate.
In an alternative embodiment, the moisture content of the hydrated composition is from about 2% to about 7%, preferably from about 3% to about 6%, more preferably from about 3.7% to about 5.5%, by weight of the hydrated composition.
The term "liquid water" refers to water used in liquid form. In embodiments of the present invention, liquid water may be used in the form of pure water or an aqueous solution.
It should be understood that in the context of the present invention, "pure water" when used in the hydration step is not intended to indicate the purity of the water, but rather to refer to the absence of intentional addition of additional substances such as solutes to the water. In the pure water used, a certain amount of impurities may be contained, including, for example, small amounts of minerals that are inherently present in the water, etc. Such water, since it is itself in a substantial proportion (e.g. 95% or more, 98% or more, 99% or more), is also included in the category of pure water referred to above. For example, liquid water having a high actual purity, such as distilled water, purified water, deionized water, or the like, may be used, or liquid water having no specific requirement for purity, such as tap water, or the like, may be used.
The term "aqueous solution" when used in the hydration step refers to a solution containing a solute with water as the solvent. In the present invention, the solute in the aqueous solution is not particularly limited, and for example, an aqueous solution having a relative humidity of about 40 to 100% RH, preferably about 60 to 98% RH, more preferably about 70 to 90% RH can be generated at room temperature, and may be, for example, pure water, an aqueous solution containing one or more selected from the group consisting of strong acids, strong bases, glycerin, inorganic salts and pharmaceutically acceptable excipients, and preferably an aqueous solution containing glycerin or inorganic salts.
The terms "aqueous solution containing glycerol", "aqueous solution of glycerol", "solution containing glycerol" and "glycerol solution" refer to a solution having water as a solvent and glycerol as a solute. The solute concentration may be adjusted according to the desired relative humidity, and may be present in the range of 0 to 100 wt%, based on the total weight of the aqueous solution, for example, may be a concentration of 10 wt%, 20 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, 55 wt%, 60 wt%, 70 wt%, 80 wt%, 90 wt%, or 100 wt%. Preferably 20 to 60 wt%, more preferably 30 to 50 wt%.
The terms "aqueous solution containing an inorganic salt", "aqueous solution of an inorganic salt", "solution containing an inorganic salt" and "inorganic salt solution" refer to a solution having water as a solvent and an inorganic salt as a solute. Examples thereof are aqueous solutions of one or more selected from the group consisting of sodium salts, potassium salts, lithium salts, magnesium salts, calcium salts, ammonium salts, cesium salts, cobalt salts and strontium salts containing anions. The anion is a counter ion in the solution, such as fluoride, chloride, bromide, iodide, acetate, carbonate, bicarbonate, nitrate, sulfate, bisulfate, chromate, phosphate, hydrogenphosphate, dihydrogenphosphate, citrate, and the like. Specific examples include, but are not limited to, aqueous solutions of one or more selected from cesium fluoride, lithium bromide, zinc bromide, lithium chloride, calcium bromide, lithium iodide, potassium acetate, potassium fluoride, magnesium chloride, sodium iodide, potassium carbonate, potassium nitrate, sodium bromide, cobalt chloride, potassium iodide, strontium chloride, sodium nitrate, sodium chloride, ammonium chloride, potassium bromide, ammonium sulfate, potassium chloride, strontium nitrate, potassium sulfate, potassium chromate, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium citrate, potassium citrate, more preferably aqueous solutions of one or more selected from cesium fluoride, lithium bromide, lithium chloride, potassium acetate, magnesium chloride, potassium carbonate, sodium bromide, potassium iodide, sodium chloride, potassium chloride, and potassium sulfate.
The aqueous solution containing the inorganic salt may be a saturated solution or an unsaturated solution. The solute concentration may be adjusted according to the desired relative humidity, and may be a concentration of 0-100% saturation, for example, a concentration of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% saturation.
The term "saturated inorganic salt solution" refers to a solution system in which an inorganic salt as a solute cannot be continuously dissolved at a certain temperature. Saturated inorganic salt solutions are typically prepared from salt of a certain purity and water (e.g., deionized water), and a portion of the salt should be maintained undissolved. Thus, for a saturated inorganic salt solution, the amount of inorganic salt used at a given temperature will generally be about 30% to 90% more than the amount required to reach saturation.
The term "Relative Humidity (RH)" refers to the density of moisture (in d) actually contained in a unit volume of air1Expressed) and saturated water vapor density at the same temperature (expressed as d)2Expressed) in percent, i.e., RH (%) ═ d1/d2X 100%. Hygrothermographs made of special temperature-and moisture-sensitive materials, e.g.
Figure BDA0001868970780000061
And 4, measuring and recording the temperature and the humidity by using an electronic temperature and humidity recorder. The term "room temperature" refers to ambient temperature, typically 15-30 ℃. The hydration method of the present invention is not limited to the temperature, and may be performed at room temperature, for example.
The term "atmospheric pressure" refers to one atmosphere of pressure. The term "slightly negative pressure" means an absolute pressure slightly lower than one atmosphere, for example, about 10 to 90kPa, preferably about 30 to 70kPa, and more preferably about 40 to 60 kPa.
The term "reconstitution time" refers to the time required to reconstitute a lyophilized or hydrated composition with a particular diluent, shaking to complete dissolution. The diluent used may be a 0.9% sodium chloride solution or sterile water for injection as is common in the art of formulation. For example, for a lyophilized or hydrated composition of 500mg size, preferably, reconstitution time of no more than 5min indicates good reconstitution and no more than 2min indicates very good reconstitution. For another example, for a lyophilized or hydrated composition of 2g size, preferably, reconstitution time of no more than 10min indicates good reconstitution and no more than 5min indicates very good reconstitution.
The term "stable" means that the CPP content and the amount of change in impurities are within limits after the CPP lyophilized composition or the hydrated composition is left under appropriate conditions for a period of time. For example, a stable hydrated CPP lyophilized composition means that it is maintained under extremely harsh conditions (e.g., 45 ℃ or 40 ℃/75% RH) for a period of time (e.g., 2 weeks or more), or under accelerated conditions (e.g., 30 ℃/60% RH or 25 ℃/60% RH) for a period of time (e.g., 6 months or more), or under storage conditions (e.g., 2-8 ℃) for a period of time (e.g., 1 year or more), with a CPP content within the range of 90% -110% over the period examined.
The term "pharmaceutically acceptable" means having a reasonable benefit to risk ratio and being effective for the intended use without undue toxicity, irritation, allergic response, and the like, upon contact with the tissue of a patient within the scope of normal medical judgment.
Method for hydrating lyophilized compositions
The present invention relates to a method for hydrating a lyophilized cyclophosphamide composition, comprising:
(a) providing an aqueous solution containing cyclophosphamide and optionally pharmaceutically acceptable excipients;
(b) freeze-drying the solution to obtain a lyophilized composition; and
(c) hydrating the lyophilized composition with liquid water, thereby obtaining a hydrated cyclophosphamide lyophilized composition.
Step (a)
In step (a), the preparation of the aqueous solution may be carried out in a solution tank. The order of adding cyclophosphamide and optionally pharmaceutically acceptable excipients to water (e.g., water for injection) is not particularly limited. For example, pharmaceutically acceptable excipients may be added first to water and then cyclophosphamide may be added. Or, the cyclophosphamide can be added into the water, and then the pharmaceutically acceptable auxiliary materials are added. Cyclophosphamide is added directly to water in the absence of pharmaceutically acceptable excipients.
In one embodiment, the cyclophosphamide used may be in the form of a hydrate (e.g., monohydrate), an anhydrate or mixtures thereof. In a preferred embodiment, cyclophosphamide is in the form of a monohydrate.
In one embodiment, the pharmaceutically acceptable excipients include, but are not limited to, one or more of sugars, carboxylic acids, amino acids, buffer salts.
The saccharide may be selected from polyols of about 5 to about 9 carbon atoms, such as mannitol, sorbitol, and galactitol, and the like; monosaccharides of about 5 to 10 carbon atoms, especially natural aldohexoses, such as glucose (dextrose), mannose, galactose, and the like; disaccharides of 12 carbon atoms, such as natural sucrose and lactose; polysaccharides, such as starch; or one or more of the above saccharides. In a preferred embodiment, the saccharide is one or more of mannitol, sorbitol, lactose.
Mannitol (Mannitol) is an isomer of sorbitol, the hydroxyl group on the second carbon atom of the two alcohols facing differently. Mannitol is readily soluble in water, is a white, transparent solid, and has a sweet taste similar to sucrose. The Mannitol may be D-Mannitol, such as commercial product of Merck
Figure BDA0001868970780000081
And a commercially available product of Roquette
Figure BDA0001868970780000082
In yet another embodiment, the carboxylic acids may be one or more selected from succinic acid, citric acid, maleic acid, tartaric acid. In a preferred embodiment, the carboxylic acids are selected from tartaric acid.
In yet another embodiment, the amino acids may be selected from one or more of arginine, serine, glycine, valine, alanine. In a preferred embodiment, the amino acids are selected from one or more of arginine, alanine.
In yet another embodiment, the buffer salts may be one or more selected from sodium or potassium salts of acetic acid, citric acid, carbonic acid, phosphoric acid. In a preferred embodiment, the buffer salts are preferably one or more of sodium carbonate and sodium bicarbonate.
In one embodiment, the amount of the optionally present pharmaceutically acceptable auxiliary material is not particularly limited and may be adjusted according to the actual situation. For example, the optionally present pharmaceutically acceptable excipients are present in an amount of about 20-90% (w/w), preferably about 25-75% (w/w), more preferably about 30-60% (w/w), even more preferably about 35-45% (w/w), such as including but not limited to 35% (w/w), 41% (w/w), 45% (w/w), and the like, based on the total weight of the pharmaceutically active ingredient and the optionally present pharmaceutically acceptable excipients.
The pharmaceutically acceptable excipients listed above are only illustrative and representative. Accordingly, the pharmaceutical formulations of the present invention are not limited to the pharmaceutically acceptable excipients listed herein above. Those skilled in the art can make various changes, modifications and equivalents to the above-described auxiliary materials according to the conventional techniques without departing from the scope of the present invention.
In one embodiment of the invention, optionally after step (a) and before step (b), sterilization is performed. For example, the aqueous solution may be sterilized and then freeze-dried. The sterilization method is not particularly limited, and for example, a filter sterilization method can be used. In one embodiment of the invention, the aqueous solution prior to lyophilization is sterilized by filtration. In a preferred embodiment, a 0.22 μm hydrophilic microporous filter is used for the filter sterilization. The microfiltration membrane material may be a Polyethersulfone (PES) material, such as Millipore (a commercially available product from Merck, Inc.)
Figure BDA0001868970780000083
And may also be a polyvinylidene fluoride (PVDF) material, such as a commercially available product from Merck corporation
Figure BDA0001868970780000084
One or more of (a). In a particularly preferred embodiment, the filter-sterilized microporous membrane may be PES material, for example Millipore, a commercially available product from Merck
Figure BDA0001868970780000085
But is not limited thereto.
Step (b)
In step (b), the aqueous solution obtained in step (a) is freeze-dried. That is, it is frozen and crystallized at a low temperature, and then the temperature is raised to cause the solvent (moisture) therein to be directly sublimated from a solid state into a gaseous state, thereby obtaining a lyophilized composition.
In one embodiment of the invention, the freeze-drying may be performed in a lyophilization flask. For example, dimensions of 30ml × 75mm (volume × height), 50ml × 73mm (volume × height) or 100ml × 100mm (volume × height) may be selected.
In one embodiment, the freezing is performed in the freezing chamber of a freeze-drying chamber. For example, the shelf of the lyophilization chamber is rapidly cooled to about-20 ℃ to about-50 ℃ at atmospheric pressure.
In a preferred embodiment, the cooling rate may be from about 0.1 to 20 deg.C/min, preferably from about 0.1 to 10 deg.C/min, more preferably from about 0.5 to 5 deg.C/min, including, but not limited to, for example, about 1 deg.C/min and the like.
In a preferred embodiment, the shelf is finally cooled to a temperature of from about-30 ℃ to about-60 ℃, preferably from about-35 ℃ to about-55 ℃, more preferably from about-40 ℃ to about-50 ℃, such as including but not limited to about-45 ℃ and the like.
In a preferred embodiment, freezing is carried out for a holding time of from about 1 to about 10 hours, preferably from about 2 to about 8 hours, more preferably from about 4 to about 6 hours, for example including but not limited to about 4 hours, 5 hours, 6 hours, and the like. In one embodiment, the warming process of freeze-drying is not particularly limited, and may be performed once, or may be performed by multiple warming, for example, two times, three times, four times, etc.
In a preferred embodiment, the warming process is done twice. For example, the shelf in the lyophilization chamber is heated for a certain period of time to a certain temperature and then maintained for a certain period of time under vacuum until the moisture content in the frozen product is about 0% to about 20%, preferably about 0% to about 10%. Continuing to heat the shelf in the freeze-drying chamber for a certain time to a certain temperature and then maintaining the shelf for a certain time under the vacuum state until the moisture content in the frozen object is about 0% to about 5%, preferably about 0% to about 3%, so as to obtain the freeze-dried composition.
In a more preferred embodiment, the first shelf heating rate is from about 0.1 to about 2 deg.C/min, preferably from about 0.1 to about 0.5 deg.C/min. In a more preferred embodiment, the temperature of the first heating of the shelf is to about-10 to about 10 deg.C, preferably about-1 to about 9 deg.C.
In a more preferred embodiment, the hold time after the first heating of the shelf is from about 10 to about 80 hours, preferably from about 15 to about 70 hours. In a more preferred embodiment, the second shelf heating rate is from about 0.1 to 2 deg.C/min, preferably from about 0.1 to 0.5 deg.C/min.
In a more preferred embodiment, the temperature of the second heated shelf is to about 15 to about 30 deg.C, preferably about 20 to about 26 deg.C. In a more preferred embodiment, the hold time after the second heating of the shelf is from about 3 to about 30 hours, preferably from about 4 to 25 hours.
The moisture content in the lyophilized composition can be determined by the Karl-Fischer direct titration Method described in USP 40-NF 35Method I <921> or by the Karl-Fischer volumetric titration Method described in the Chinese pharmacopoeia 2015 edition three-part general rule <0832 > moisture determination.
In one embodiment of the invention, the moisture content of the lyophilized composition is not greater than about 9%, preferably not greater than about 7%, more preferably not greater than about 5.5%, and most preferably not greater than about 3.5% by weight relative to the weight of cyclophosphamide monohydrate.
In alternative embodiments, the moisture content in the lyophilized composition is not greater than about 5%, preferably not greater than about 4%, more preferably not greater than about 3%, most preferably not greater than about 2%, relative to the weight of the lyophilized composition, including for example, but not limited to, not greater than about 3.0%, about 2.9%, about 2.8%, about 2.7%, about 2.6%, about 2.5%, about 2.4%, about 2.3%, about 2.2%, about 2.1%, or about 2.0%, and the like.
Step (c)
In step (c), the lyophilized composition is hydrated using liquid water, thereby obtaining a hydrated lyophilized composition.
The liquid water is water that is liquid under the conditions under which hydration is performed. For example, pure water or an aqueous solution can be used. Pure water that may be used includes, but is not limited to, purified water, distilled water, deionized water, tap water, and the like. The aqueous solution is an aqueous solution which can be produced at room temperature and has a relative humidity of about 40 to 100% RH, preferably about 60 to 98% RH, more preferably about 70 to 90% RH, and for example, may be an aqueous solution containing one or more selected from the group consisting of a strong acid, a strong base, glycerol, an inorganic salt and a pharmaceutically acceptable auxiliary, preferably an aqueous solution containing glycerol or an inorganic salt. The aqueous solution used may be sterilized by a selected sterilization means depending on the nature of the solution, for example by filtration or autoclaving.
In a preferred embodiment, the aqueous solution containing a strong acid is an aqueous solution containing sulfuric acid.
In a preferred embodiment, the aqueous solution containing a strong base is an aqueous solution containing potassium hydroxide or sodium hydroxide.
In one embodiment of the present invention, the aqueous solution containing an inorganic salt is an aqueous solution of one or more selected from sodium salt, potassium salt, lithium salt, magnesium salt, calcium salt, ammonium salt, cesium salt, cobalt salt and strontium salt containing an anion, and preferably an aqueous solution of one or more selected from sodium salt, potassium salt, lithium salt and magnesium salt containing an anion. The anion is a counter ion in the solution, such as fluoride, chloride, bromide, iodide, acetate, carbonate, bicarbonate, nitrate, sulfate, bisulfate, chromate, phosphate, hydrogenphosphate, dihydrogenphosphate, citrate, and the like. Specific examples are aqueous solutions containing one or more of cesium fluoride, lithium bromide, zinc bromide, lithium chloride, calcium bromide, lithium iodide, potassium acetate, potassium fluoride, magnesium chloride, sodium iodide, potassium carbonate, potassium nitrate, sodium bromide, cobalt chloride, potassium iodide, strontium chloride, sodium nitrate, sodium chloride, ammonium chloride, potassium bromide, ammonium sulfate, potassium chloride, strontium nitrate, potassium sulfate, potassium chromate, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium citrate, potassium citrate, and more preferably aqueous solutions containing one or more of cesium fluoride, lithium bromide, lithium chloride, potassium acetate, magnesium chloride, potassium carbonate, sodium bromide, potassium iodide, sodium chloride, potassium chloride, and potassium sulfate.
In a preferred embodiment, the concentration of glycerol in the glycerol-containing aqueous solution may be adjusted according to the desired relative humidity, and may be in the range of 0 to 100 wt%, for example, may be in the concentration of 10 wt%, 20 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, 55 wt%, 60 wt%, 70 wt%, 80 wt%, 90 wt%, or 100 wt%, based on the total weight of the aqueous solution. Preferably 20 to 60 wt%, more preferably 30 to 50 wt%.
In a preferred embodiment, the concentration of the inorganic salt in the aqueous solution containing the inorganic salt may be adjusted according to the desired relative humidity, and may be a concentration of 0 to 100% saturation, for example, a concentration of 5% saturation, 10% saturation, 20% saturation, 30% saturation, 40% saturation, 50% saturation, 60% saturation, 70% saturation, 80% saturation, 90% saturation or 100% saturation.
In still another embodiment of the present invention, the aqueous solution containing pharmaceutically acceptable excipients is an aqueous solution containing one or more selected from the group consisting of saccharides, organic solvents, and surfactants.
In another embodiment of the present invention, the aqueous solution containing saccharides may be selected from polyols containing about 5 to about 9 carbon atoms, such as mannitol, sorbitol, galactitol, and the like; monosaccharides of about 5 to 10 carbon atoms, especially natural aldohexoses, such as glucose (dextrose), mannose, galactose, and the like; disaccharides of 12 carbon atoms, such as natural sucrose and lactose; polysaccharides, such as starch; or an aqueous solution of one or more of the above saccharides. In a preferred embodiment, the aqueous solution containing saccharides is an aqueous solution containing one or more of mannitol, sorbitol, lactose.
In another embodiment of the present invention, the aqueous solution containing an organic solvent may be an aqueous solution selected from one or more of methanol, ethanol, propylene glycol, polyethylene glycol 200, polyethylene glycol 400, and polyethylene glycol 600.
In still another embodiment of the present invention, the concentration of the organic solvent in the aqueous solution containing the organic solvent may be adjusted according to the desired relative humidity.
In a preferred embodiment, the surfactant is selected from Sodium Dodecyl Sulfate (SDS), ethylene oxide-propylene oxide block copolymers, polyvinyl ethers, sorbitan esters, polyoxyethylene fatty acid esters, polyoxyethylene castor oil and derivatives thereof, polyethylene glycol fatty acid esters, or combinations thereof.
In a more preferred embodiment, the surfactant is one or more selected from the group consisting of ethylene oxide-propylene oxide block copolymers, polyoxyethylene sorbitan esters, polyoxyethylene castor oils and derivatives thereof, most preferably Poloxamer188, polyoxyethylene (20) sorbitan monooleate (r)
Figure BDA0001868970780000111
80) And polyoxyethylene hydrogenated castor oil (
Figure BDA0001868970780000112
RH 40).
In yet another embodiment of the present invention, the concentration of the surfactant in the surfactant-containing aqueous solution may be adjusted according to the desired relative humidity.
If desired, the liquid water may be sterilized prior to use, for example by filtration or steam sterilization.
The amount of liquid water used in the method of the invention is not particularly limited and depends primarily on its exposed surface area and the volume of the lyophilization chamber. Provided that the amount of liquid water introduced is such that the relative humidity of the lyophilization chamber is maintained between about 40% RH and about 100% RH, preferably between about 60% RH and about 98% RH, and more preferably between about 70% RH and about 90% RH. For example, when the volume of the lyophilization chamber is 0.2m3When the exposed surface area of the aqueous solution is 0.1 to 0.2m2In this case, the amount of aqueous solution is from about 100 to about 1000 g.
The manner of hydration using liquid water in the present invention is not particularly limited, and liquid water can be introduced by various methods to maintain the desired relative humidity in the lyophilization chamber, for example, about 40-100% RH, preferably about 60-98% RH, and more preferably about 70-90% RH at ambient temperature and pressure or at ambient temperature and slightly negative pressure. For example, the following exemplary methods may be employed: 1) after the freeze drying is finished, after the freeze drying chamber is returned to the room temperature of normal pressure, opening a front box door, placing sterile liquid water in a bottom plate or a shelf tray of the freeze drying chamber, closing the box door, and hydrating at normal temperature and normal pressure or hydrating at normal temperature and normal pressure under normal temperature and micro negative pressure; 2) after the freeze drying is finished, after the freeze drying chamber is returned to the normal pressure room temperature, liquid water is input into a bottom plate or a shelf tray of the freeze drying chamber through a pipeline and is hydrated at the normal temperature and the normal pressure or is hydrated at the normal temperature and the micro negative pressure; 3) after the freeze drying is finished, after the freeze drying chamber is returned to the room temperature at normal pressure, the electronic controller opens the closed container of the liquid water stored in the bottom plate or the shelf tray of the freeze drying chamber in advance, and the liquid water is hydrated at normal temperature and normal pressure or at normal temperature and under slight negative pressure. Without intending to be bound by any theory, it is believed that the final hydration results are not significantly affected by hydration at atmospheric pressure and micro-negative pressure, but micro-negative pressure can accelerate the completion of the hydration process, thereby increasing the efficiency of industrial production.
Similarly, the moisture content in the hydrated lyophilized composition can be determined by the Karl-Fischer direct titration Method described in USP 40-NF 35Method I <921> or by the Karl-Fischer volumetric titration Method described in the Chinese pharmacopoeia 2015 edition three general rules <0832 > water determination.
The hydration in step (c) may be carried out at ambient temperature, for example at 15-30 ℃.
The hydration process in step (c) may be carried out at normal pressure or at a slight negative pressure. For example, the micro-negative pressure may be about 10 to 90kPa, preferably about 30 to 70kPa, more preferably about 40 to 60kPa, for example about 60 kPa.
After hydration in step (c), the moisture content in the resulting hydrated composition is about 4-12%, preferably about 5-10%, more preferably about 6-9%, more preferably about 6.5-9.0%, including for example but not limited to about 6.5%, about 6.6%, about 6.7%, about 6.8%, about 6.9%, about 7.0%, about 7.1%, about 7.2%, about 7.3%, about 7.4%, about 7.5%, about 7.6%, about 7.7%, about 7.8%, about 7.9%, about 8.0%, about 8.1%, about 8.2%, about 8.3%, about 8.4%, about 8.5%, about 8.6%, about 8.7%, about 8.8%, about 8.9% and about 9.0%, relative to cyclophosphamide monohydrate.
Alternatively, after hydration in step (c), the moisture content in the hydrated composition is about 2-7%, preferably about 3-6%, more preferably about 3.7-5.5%, relative to the weight of the hydrated composition, for example including but not limited to about 3.8%, about 3.9%, 4.0%, about 4.1%, about 4.2%, about 4.3%, about 4.4%, about 4.5%, about 4.6%, about 4.7%, about 4.8%, about 4.9%, about 5.0%, about 5.1%, about 5.2%, about 5.3%, about 5.4% and about 5.5%.
When the moisture content of the hydrated composition is above about 12% (relative to cyclophosphamide monohydrate) or above about 7% (relative to the hydrated composition), the resulting product is pharmaceutically unsightly and unstable. When the hydration composition has insufficient water, especially less than about 4% (relative to cyclophosphamide monohydrate), the hydration composition will melt at room temperature. The moisture content is too high or too low, neither of the CPP lyophilized compositions can maintain the integrity of the lyophilized cake during storage.
The time for hydration in step (c) may be adjusted according to the actual circumstances.
For example, for a CPP lyophilized composition of 500mg size, about 8h or longer, about 12h or longer, about 16h or longer, about 20h or longer, about 24h or longer, about 32h or longer, about 40h or longer may be performed, or about 4-40h, such as about 8-32h, about 12-28h, about 16h, about 24h, and the like may be performed.
For example, for a CPP lyophilized composition of 2g size, about 12h or longer, about 24h or longer, about 36h or longer, about 48h or longer, about 72h or longer, about 96h or longer, about 120h or longer may be performed, or about 12-120h, such as about 12-48h, about 12-36h, about 48-120h, about 48-96h, about 24h, about 72h, etc. may be performed.
Accordingly, the present invention also relates to a hydrated lyophilized CPP composition or a hydrated CPP lyophilized composition obtained by the method of the present invention.
In one embodiment, the hydrated lyophilized composition is uniform and full in appearance. In another embodiment, the lyophilized composition upon hydration has one or more of the following characteristics: a moisture content of about 4-12%, preferably about 5-10%, more preferably about 6-9%, more preferably about 6.5-9.0% relative to cyclophosphamide monohydrate; the storage is stable and the degradation is not easy; the volume is kept unchanged, and the texture is loose; the appearance is excellent; is sterile and free from contamination.
Advantageous effects
For pharmaceutically active ingredients such as CPP, stability is a requirement for moisture content, and stability is poor when moisture content is too high or too low. Therefore, maintaining a certain moisture content is critical to its stability. The problem with the past and current preparation of lyophilized products is that it is convenient to lyophilize the water in the composition to a range of contents using a simple lyophilization process; however, in the commercial production process, it is very difficult to maintain the moisture content in all the freeze-dried bottles uniformly by controlling the freeze-drying process. There are several methods of hydrating the freeze-dried product. For example, sterile air/nitrogen at a certain humidity is introduced into the lyophilization chamber, but the preparation of sterile air/nitrogen at a given humidity is difficult, the relative humidity of the lyophilization chamber is not easy to control, and the sterility of the entire process is difficult to guarantee. A problem with both the past and current methods is that each step requires opening the machine or lyophilization chamber, thereby exposing the contents to the ambient (potentially contaminating) air. Or a certain calculated amount of hot water vapor is introduced into the freeze-drying chamber in a short time while maintaining a high vacuum degree, but the method is complicated in calculation and difficult in hot water vapor preparation and introduction operation. In addition, due to the fact that the water vapor is easy to generate supersaturation, water drops are easy to generate around the freeze-dried penicillin bottle or in the freeze-drying box, so that the freeze-dried composition is polluted, and the hydration of the freeze-dried composition is not uniform. Moreover, the above methods are difficult to be commercially produced.
Various embodiments of the present invention solve these problems, and a lyophilized composition comprising a pharmaceutically active ingredient CPP is hydrated by liquid water, so that a hydrated lyophilized composition having a moisture content within a desired range can be obtained, thereby effectively solving the problem of poor storage stability. Further, the obtained lyophilized formulation has better storage stability than the past or current methods. In addition, when the CPP freeze-dried composition is hydrated by using liquid water or aqueous solution, the operation is superior, and the uniform moisture content and small batch-to-batch difference of all hydrated freeze-dried preparations in a freeze-drying chamber can be ensured.
Compared with other methods, the hydration method of the invention is simple, convenient and easy to operate, safe, low in cost, and capable of effectively reducing the difference between batches, and the obtained product has better storage stability and is more suitable for commercial production.
Examples
The technical solutions will be further described below by the following specific examples, but not by way of limitation. It should be noted that the described embodiments are only illustrative and are not intended to limit the scope of the present invention. The invention is capable of other embodiments or of being practiced or carried out in various ways. All percentages, parts, ratios, etc. herein are by weight unless otherwise indicated. Unless otherwise indicated, the solutions referred to herein are aqueous solutions.
Pharmaceutical raw materials and adjuvants used herein are commercially available. For example, cyclophosphamide is available from the Hongyong pharmaceutical industry or from Hetero and mannitol from Merck.
Evaluation and measurement method for physicochemical properties
And (3) moisture determination: measured by Karl-Fischer volumetric titration as described in the Chinese pharmacopoeia 2015 edition three general rules <0832 moisture determination >. The water content was determined using a Karl-Fischer moisture meter (model MKS AT-520, manufacturer KEM): precisely weighing a proper amount of a test sample (such as an active ingredient CPP, a CPP freeze-dried composition or a hydrated CPP freeze-dried composition, and consuming about 1-5ml of Fischer's reagent), placing the test sample in a dry conical flask with a plug, adding a proper amount of anhydrous methanol, and titrating with the Fischer's reagent under continuous shaking (or stirring) until the solution is changed from light yellow to reddish brown. A blank test is also performed, and the calculation is carried out according to the following formula:
Figure BDA0001868970780000131
wherein A is the volume of the Hough's test solution consumed by the test sample, and ml;
b is the volume of the Fischer's reagent consumed by the blank, ml;
f is the weight of water, mg, corresponding to each ml of Fischer's reagent;
w is the weight of the test article, mg.
Content determination:
take 500mg of a hydrated CPP lyophilized composition as an example. Preparation of sample stock solution (1mg/ml of anhydrous cyclophosphamide): adding a proper amount of pure water into a sample bottle, shaking until the sample is dissolved, transferring the sample into a 500ml measuring flask, washing the sample with the pure water for multiple times to ensure that the sample is completely transferred into the measuring flask, and then fixing the volume to the scale with the pure water and shaking up. Sample solution (0.5mg/ml of anhydrous cyclophosphamide) preparation: transferring 25ml of sample stock solution and 5.0ml of internal control solution (185 mg of ethyl p-hydroxybenzoate control is accurately weighed in a 1000ml measuring flask, adding 250ml of ethanol, shaking to dissolve, adding pure water to a constant volume and shaking uniformly) into a 50ml measuring flask, adding pure water to a constant volume, and shaking uniformly to perform HPLC analysis.
The HPLC analytical parameters were as follows:
chromatographic column WatersμBondpak C18,3.9mm×300mm,10μm
Mobile phase Acetonitrile water ═ 30:70(v/v)
Detection wavelength 195nm
Column temperature
25℃
Flow rate of flow 1.5ml/min
Sample introduction volume 25μL
Run time 15min
And (3) determination of redissolution time: transferring 25ml of 0.9% sodium chloride solution into a vial containing the sample (500mg of the hydrated CPP lyophilized composition), or transferring 100ml of 0.9% sodium chloride solution into a vial containing the sample (2g of the hydrated CPP lyophilized composition), shaking the vial by hand to dissolve the sample completely, and observing and recording the redissolution time.
EXAMPLE 1 preparation of different aqueous solutions
1. Preparation of different sodium bromide solutions
29.5g and 68.9g of sodium bromide are respectively put into a beaker with 100ml of purified water and stirred at room temperature until the sodium bromide is clear, thus obtaining sodium bromide solutions with 30 percent and 70 percent of saturation.
2. Preparation of different sodium chloride solutions
10.8g and 25.3g of sodium chloride are respectively put into a beaker filled with 100ml of purified water, and stirred at room temperature until the solution is clear, thus obtaining sodium chloride solutions with 30 percent and 70 percent of saturation.
34g of sodium chloride is weighed and placed in a beaker with 100ml of purified water, stirred at room temperature until the mixture is clear, and then 12g of sodium chloride is added and stirred, so that a sodium chloride solution with the saturation of 100% is obtained.
3. Preparation of different potassium chloride solutions
Respectively taking 11.2g and 26.0g of potassium chloride, placing the potassium chloride and the potassium chloride into a beaker filled with 100ml of purified water, and stirring the mixture at room temperature until the mixture is clear, thus obtaining potassium chloride solutions with 30 percent and 70 percent of saturation.
Weighing 40g of potassium chloride, placing the potassium chloride in a beaker filled with 100ml of purified water, heating to 60 ℃, stirring until the potassium chloride is clear, cooling to room temperature, adding 8g of potassium chloride, and stirring to obtain a potassium chloride solution with the saturation of 100%.
4. Preparation of different potassium sulfate solutions
3.9g and 9.1g of potassium sulfate are respectively put into a beaker with 100ml of purified water and stirred at room temperature until the solution is clear, thus obtaining potassium sulfate solution with 30 percent and 70 percent of saturation.
Weighing 15g of potassium sulfate, placing the potassium sulfate in a beaker filled with 100ml of purified water, heating to 60 ℃, stirring to be clear, cooling to room temperature, adding 5g of potassium sulfate, and stirring to obtain a potassium sulfate solution with the saturation of 100%.
5. Preparation of different surfactant solutions
1g and 5g of Sodium Dodecyl Sulfate (SDS) are respectively put into a beaker with 100ml of purified water and stirred at room temperature until the solution is clear, thus obtaining SDS solutions with the concentration of 1 percent and 5 percent respectively.
Placing 1g and 5g of Tween 80(Tween 80) in a beaker containing 100ml of purified water, and stirring at room temperature until the solution is clear, so as to obtain Tween 80 solutions with the concentrations of 1% and 5%, respectively.
6. Preparation of different glycerol solutions
Putting 30g of glycerol into a beaker filled with 70g of purified water, and stirring at room temperature until the glycerol is clear, so as to obtain a glycerol solution with the concentration of 30% w/w;
putting 40g of glycerol into a beaker filled with 60g of purified water, and stirring at room temperature until the glycerol is clear, so as to obtain a glycerol solution with the concentration of 40% w/w;
50g of glycerol is put into a beaker filled with 50g of purified water, and stirred at room temperature until the glycerol is clear, so that the glycerol solution with the concentration of 50% w/w is obtained.
7. Preparation of saturated mannitol solution
Weighing 18g of mannitol, placing in a beaker containing 100ml of purified water, stirring at room temperature until the mixture is clear, adding 5g of mannitol, and stirring to obtain a saturated mannitol solution.
The aqueous solutions of different saturation or concentration and purified water were placed on the shelf of the dryer, the lid was closed (i.e., at 0 f), and the relative humidity in the dryer was recorded every 30min, with the results shown in table 1-1 below.
The results show that aqueous solutions of different saturation or concentration, as well as purified water, can provide relative humidity above 50% RH after 0.5h in the desiccator. By varying the type of aqueous solution, or varying the saturation or concentration of solutes in the aqueous solution, various levels of relative humidity can be obtained.
Figure BDA0001868970780000161
Figure BDA0001868970780000171
Example preparation and input of 270% saturation sodium chloride solution
Preparation of 1.70% saturated sodium chloride solution
12kg of purified water is placed in a stainless steel bucket, 3.04kg of sodium chloride is weighed and poured into the water, and the mixture is stirred and dissolved until the mixture is clear, so that 25.3% (w/v) sodium chloride solution (namely, about 70% saturated sodium chloride solution) is obtained.
Input and relative humidity of 2.70% saturation sodium chloride solution
The sodium chloride solution of 70% saturation was sterilized by autoclaving (121 ℃ C., about 15min) and then sub-packaged in 16 stainless steel trays (tray size 300 mm. times.220 mm. times.50 mm). In a class A clean area, the front door of a freeze-drying box (model DG-2010BSCSIP/CIP, Shanghai Co., Ltd.) is opened, a stainless steel tray filled with a 70% saturated sodium chloride solution is pushed into a 9 th partition plate (plate layer size 1200 mm. times.900 mm) of the freeze-drying machine, and the front door of the freeze-drying box is closed. Controlling the temperature of the partition board to be about 25 ℃, vacuumizing to the vacuum degree of about 60kPa, and closing the partition board valve. The relative humidity of the front box of the lyophilizer was recorded over time and the results are shown in Table 2-1.
TABLE 2-170% relative humidity of saturated sodium chloride solution in the lyophilization chamber (25 ℃, about 60kPa)
Time point (h) RH％ Time point (h) RH％
0 45.8 6.5 80.2
0.5 60.7 7.0 80.2
1.0 67.2 7.5 80.7
1.5 72.0 8.0 80.2
2.0 74.6 8.5 80.2
2.5 76.8 9.0 80.2
3.0 77.6 9.5 80.7
3.5 78.9 10.0 80.2
4.0 79.4 10.5 80.7
4.5 79.8 11.0 80.2
5.0 80.2 11.5 80.7
5.5 80.2 12.0 80.7
6.0 80.2
As can be seen from Table 2-1, the relative humidity of 75-85% RH is generated after the 70% saturation sodium chloride solution is placed in the freeze drying box (25 ℃, about 60kPa) for about 2h, and a sufficiently stable relative humidity environment can be provided for hydration.
Example 3 hydration of lyophilized compositions with saturated sodium bromide solution (relative humidity 60% RH at room temperature)
1. Method step
Preparing a saturated sodium bromide solution: weighing 520g of purified water in a beaker, heating to 40 ℃, adding 520g of sodium bromide, stirring to completely dissolve the sodium bromide, cooling to room temperature, adding 156g of sodium bromide, and stirring to obtain a sodium bromide saturated solution.
The CPP freeze-dried composition is prepared and hydrated according to the following method and steps:
1) weighing 375g of mannitol, putting into 15kg of water for injection, adding 534.5g of CPP monohydrate, stirring for dissolution, filtering and sterilizing by using a 0.22 mu m filter membrane, and subpackaging 15.91 g/bottle into 30cc or 50cc tubular penicillin bottles (Schott company) and half-pressure stoppers (brominated butyl rubber stoppers, West company);
2) placing the semi-stoppered penicillin bottles on shelves of a freeze-drying box (model LYO-0.5, Shanghai Toufong Fulong science and technology Co., Ltd.), starting a freeze dryer, reducing the temperature of the shelves to-30 ℃ within 1h, and maintaining for 7 h;
3) starting vacuum, heating the shelf when the vacuum degree reaches 90Pa, and maintaining the temperature of the shelf for about 28 hours at 3 ℃ within 1 hour; and heating the shelf again to make the temperature of the shelf reach 25 ℃ within 1h, and maintaining for about 10h, and finishing the freeze-drying process to obtain the CPP freeze-dried composition.
4) The saturated sodium bromide solution was placed in a desiccator and allowed to stand for 24 h. And taking the CPP freeze-dried composition out of the freeze-drying box, semi-plugging, putting the CPP freeze-dried composition into a dryer, respectively plugging penicillin bottles filled with the hydrated CPP freeze-dried composition in the 8 th, 16 th and 40 th hours, taking out, and pressurizing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
2. Evaluation of the Properties of the hydrated Freeze-dried composition
1) Appearance of the product
In the desiccator, the CPP lyophilized composition hydrated with a saturated sodium bromide solution appeared to be in a uniform and full state in the vial.
2) Physical and chemical properties
The moisture content, CPP content and reconstitution time of the CPP lyophilized composition using a saturated sodium bromide solution in a desiccator were determined. The results are shown in the following Table 3-1.
TABLE 3-1 physicochemical Properties of the hydrated CPP lyophilized composition
Hydration time (h) Water content%1 Water content%2 Redissolution time (min) Content of CPP%
0 2.1 3.6 9.5 103.1
8 4.1 7.0 1.2 100.3
16 4.0 6.8 1.2 96.1
40 4.0 6.6 1.7 103.2
1The% moisture content is calculated relative to the weight of the lyophilized composition.
2The% moisture content is calculated as weight relative to CPP monohydrate.
As can be seen from the table 3-1, the CPP freeze-dried compositions hydrated by the saturated sodium bromide solution for 8h and 16h meet the requirements on appearance, moisture content, CPP content and re-dissolution time.
Example 4 lyophilized composition hydrated with saturated sodium chloride solution (relative humidity 75% RH at room temperature)
1. Method step
Preparing a saturated sodium chloride solution: weighing 520g of purified water in a beaker, adding 187.2g of sodium chloride, stirring to completely dissolve the sodium chloride, adding 57g of sodium chloride, and stirring to obtain a sodium chloride saturated solution.
The CPP lyophilized composition was obtained according to the methods and procedures of 1) to 3) of example 3.
Then hydrating according to the following method:
4) and opening the air inlet valve to enable sterile air to enter the freeze-drying box, relieving the vacuum state and closing the air inlet valve.
The front door of the freeze-drying box (model LYO-0.5, Fulong technologies, Inc., Shanghai) was opened, and the front door was locked by placing the steam-sterilized saturated sodium chloride solution in a sterile tray on the bottom shelf (shelf 4). And taking out the penicillin bottles filled with the hydrated CPP freeze-dried composition at 16h and 24h respectively, and pressurizing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
Or 4') placing the saturated sodium chloride solution in a dryer and standing for 24 h. And taking the CPP freeze-dried composition out of the freeze-drying box, semi-plugging, putting the CPP freeze-dried composition into a dryer, respectively plugging penicillin bottles filled with the hydrated CPP freeze-dried composition in the 8 th, 16 th and 40 th hours, taking out, and pressurizing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
2. Evaluation of the Properties of the hydrated Freeze-dried composition
1) Appearance of the product
The CPP lyophilized composition hydrated with a saturated sodium chloride solution in the lyophilization chamber and dryer all appeared to be in a uniform and filled state in the vial.
2) Physical and chemical properties
The moisture content, the CPP content and the reconstitution time of the CPP lyophilized composition hydrated in a lyophilizer by using a saturated sodium chloride solution are respectively determined. In addition, the CPP lyophilized compositions hydrated for 16h and 24h were placed in an oven at 45 ℃ and sampled after 1 week and 2 weeks, respectively, to determine the CPP content. The results are shown in the following Table 4-1.
TABLE 4-1 physicochemical Properties of the hydrated CPP lyophilized composition
Figure BDA0001868970780000201
1The% moisture content is calculated relative to the weight of the lyophilized composition.
2The% moisture content is calculated as weight relative to CPP monohydrate.
The moisture content, CPP content and reconstitution time of the hydrated CPP lyophilized composition obtained using a saturated sodium chloride solution in a desiccator were measured, respectively. In addition, the CPP lyophilized composition hydrated for 16h is placed in an oven at 45 ℃, and samples are taken after 1 week and 2 weeks, respectively, to determine the CPP content. The CPP lyophilized composition hydrated for 16h was placed in a 40 ℃/75% RH stability chamber, sampled at 1 month and 3 months, respectively, and the CPP content was determined and compared with the CPP monohydrate obtained by the hydration method of the prior art. The results are shown in Table 4-2 below.
TABLE 4-2 physicochemical Properties of the hydrated CPP lyophilized composition
Figure BDA0001868970780000211
1The% moisture content is calculated as weight relative to CPP monohydrate.
2Data are from US 4,537,883.
As can be seen from Table 4-1, the CPP lyophilized composition which had not been hydrated with a saturated sodium chloride solution had a moisture content of 3.6% and was unstable when left to stand at 45 ℃ for 1 week. In contrast, the CPP freeze-dried composition hydrated by using a saturated sodium chloride solution in the freeze-drying box meets the requirements on moisture content, CPP content and reconstitution time. Even if the CPP is placed in an environment of 45 ℃ for 3 weeks, the content of the CPP is not less than 99 percent, and the CPP shows very good stability. In addition, when the CPP freeze-dried composition is hydrated by using a saturated sodium chloride solution in a freeze-drying box, the hydrated CPP freeze-dried composition with good performance can be obtained after 16h and 24h of hydration. Moreover, no matter where the saturated sodium chloride solution is placed in the shelf of the freeze-drying box, a stable hydration environment can be provided, so that the qualified hydration CPP freeze-drying composition can be obtained.
As can be seen from Table 4-2, the reconstitution time of the CPP lyophilized composition without hydration with saturated sodium chloride solution reaches 9.5min, which is not satisfactory. As can be seen from Table 4-1, the CPP lyophilized composition without hydration had a moisture content of 3.6% and was unstable when left in an environment of 45 ℃ for 1 week. In contrast, the CPP freeze-dried composition hydrated by using the saturated sodium chloride solution in the dryer has satisfactory moisture content, CPP content and reconstitution time. More particularly, the CPP lyophilized composition hydrated for 16h has good stability after being placed in an environment of 45 ℃ for 2 weeks, and is also very stable after being placed in an extremely severe environment (40 ℃/75% RH) for 1 month and 3 months. And the stability in this environment is even better than that of the active ingredient CPP monohydrate.
Furthermore, after the lyophilized composition containing CPP and mannitol was hydrated by the hydration method disclosed in US 4,537,883 (column 8 of the specification, Table 4), the CPP content after 1 week and 2 weeks at 45 ℃ was only 94% and 76%, respectively. In contrast, in the present invention, the CPP content of the CPP lyophilized composition after being hydrated with a saturated sodium chloride solution in a lyophilization chamber or a dryer when being left at 45 ℃ for 1 week, 2 weeks, or 3 weeks was 98% or more, indicating that the CPP lyophilized composition after being hydrated with a saturated sodium chloride solution of the present invention has better stability.
Example 5 hydration of lyophilized compositions with saturated potassium chloride solution (85% RH relative humidity at room temperature)
1. Method step
Preparing a saturated potassium chloride solution: weighing 100g of purified water, placing the purified water in a beaker, adding 45g of potassium chloride, heating to 70 ℃, stirring while heating until the solution is clear, stopping heating, and cooling the solution to room temperature to obtain a saturated potassium chloride solution.
The CPP lyophilized composition was obtained according to the methods and procedures of 1) to 3) of example 3.
Then hydrating according to the following method: and opening the air inlet valve to enable sterile air to enter the freeze-drying box, relieving the vacuum state and closing the air inlet valve. The front door of the freeze-drying box is opened, the saturated potassium chloride solution which is sterilized by steam is placed in a sterile tray at the bottommost layer of the shelf, and the front door is locked. And (5) respectively plugging the penicillin bottles filled with the hydrated CPP freeze-dried composition at 8h, 12h and 16h, taking out, and pressing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
2. Evaluation of the Properties of the hydrated Freeze-dried composition
1) Appearance of the product
In the freeze-drying box, the CPP freeze-drying composition hydrated by using a saturated potassium chloride solution presents a uniform and full state in a penicillin bottle.
2) Physical and chemical properties
The moisture content, CPP content, and reconstitution time of the CPP lyophilized composition hydrated in the lyophilizer using a saturated potassium chloride solution were measured, and the results are shown in the following table 5-1.
TABLE 5-1 physicochemical Properties of the hydrated CPP lyophilized composition
Figure BDA0001868970780000221
1The% moisture content is calculated as weight relative to CPP monohydrate.
As can be seen from Table 5-1, the CPP lyophilized composition which had not been hydrated with a saturated potassium chloride solution had a moisture content of 1.9%, and was unstable. The water content, the CPP content and the redissolution time of the CPP freeze-dried composition hydrated by using the saturated potassium chloride solution in the freeze-drying box all meet the requirements. And the CPP freeze-dried composition hydrated for 24 hours by using a saturated potassium chloride solution has good stability after being placed in an environment of 45 ℃ for 2 weeks.
Example 6 hydration of lyophilized compositions Using saturated potassium sulfate solution (relative humidity 98% RH at room temperature)
1. Method step
Preparing a saturated potassium sulfate solution: 70g of potassium sulfate is weighed into 520ml of water, heated to 40 ℃ for dissolution, and the container is placed into cold water for cooling after clarification. Then 40g of potassium sulfate is added to obtain saturated potassium sulfate solution.
The CPP lyophilized composition was obtained according to the methods and procedures of 1) to 3) of example 3.
Then hydrating according to the following method: placing the saturated potassium sulfate solution in a dryer, and standing for 24 h. And taking the CPP freeze-dried composition and half tamponade, putting the CPP freeze-dried composition into a dryer, respectively tamponading penicillin bottles filled with the hydrated CPP freeze-dried composition in the 8 th, 16 th and 40 th hours, taking out, and pressurizing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
2. Evaluation of the Properties of the hydrated Freeze-dried composition
1) Appearance of the product
The CPP lyophilized composition hydrated in a desiccator with a saturated potassium sulfate solution appeared to be in a uniform and filled state in the vial.
2) Physical and chemical properties
The moisture content, CPP content and reconstitution time of the hydrated CPP lyophilized composition obtained using a saturated potassium sulfate solution in a desiccator were measured, respectively. In addition, the CPP lyophilized composition hydrated for 16h is placed in an oven at 45 ℃, and samples are taken after 1 week and 2 weeks, respectively, to determine the CPP content. The CPP freeze-dried composition hydrated for 16h is placed in a 40 ℃/75% RH stability box, samples are taken at 1 month and 3 months respectively, and the CPP content is determined. The results are shown in Table 6-1 below.
TABLE 6-1 physicochemical Properties of the hydrated CPP lyophilized composition
Figure BDA0001868970780000231
1The% moisture content is calculated as weight relative to CPP monohydrate.
As can be seen from Table 6-1, the CPP lyophilized composition after hydration in the desiccator using the saturated potassium sulfate solution has satisfactory moisture content, CPP content and reconstitution time. And the CPP freeze-dried composition hydrated for 16h has good stability when placed in an environment at 45 ℃ for 2 weeks, and is also very stable when placed in an extremely severe environment (40 ℃/75% RH) for 1 month and 3 months. And the stability in this environment is even better than that of the active ingredient CPP monohydrate.
Example 7 hydration of lyophilized compositions Using purified Water (100% RH relative humidity at room temperature)
1. Method step
The CPP freeze-dried composition is prepared and hydrated according to the following method and steps:
1) weighing 180g of mannitol, placing in 7.2kg of water for injection, adding 257g of CPP monohydrate, stirring for dissolution, filtering and sterilizing by using a 0.22 mu m filter membrane, and subpackaging in 63.64 g/bottle into 100cc tubular penicillin bottles (Schott company) and half-press stoppers (brominated butyl rubber stoppers, West company);
2) placing the semi-stoppered penicillin bottles on shelves of a freeze-drying box (model LYO-0.5, Shanghai Toufong Fulong science and technology Co., Ltd.), starting a freeze dryer, reducing the temperature of the shelves to 0 ℃ at the speed of 1 ℃/min, and maintaining for about 2 h; reducing the temperature of the shelf to-40 ℃ at the speed of 1 ℃/min, and maintaining for about 7 hours;
3) heating the shelf to 4 ℃ at the speed of 0.5 ℃/min, and maintaining the temperature for about 61 hours; the shelf temperature was raised to 25 ℃ at a rate of 0.5 ℃/min for about 15 hours. And (5) finishing the freeze-drying procedure to obtain the CPP freeze-dried composition.
4) And opening an air inlet valve of the freeze-drying box to enable sterile air to enter the freeze-drying box, relieving the vacuum state and closing the air inlet valve. The front door of a freeze-drying box (model LYO-0.5, Fulong technologies, Inc. of Shanghai east) was opened, and steam-sterilized pure water was placed in a sterile tray at the lowermost layer of the shelf, and the front door was locked. And (5) respectively plugging penicillin bottles filled with the hydrated CPP freeze-dried composition at 24h, 48h and 72h, taking out, and pressing an aluminum-plastic combined cover to obtain 2g of the hydrated CPP freeze-dried composition.
Or 4') opening the air inlet valve of the freeze-drying box to make sterile air enter the freeze-drying box, relieving the vacuum state and closing the air inlet valve. The front door of a freeze-drying box (model LYO-0.5, Fulong technologies, Inc. of Shanghai east) was opened, and steam-sterilized pure water was placed in a sterile tray at the lowermost layer of the shelf, and the front door was locked. And vacuumizing the front chamber of the freeze-drying box at room temperature, stopping vacuumizing when the pressure is about 60kPa, closing a septum valve, and starting hydration timing. And (5) plugging the penicillin bottle filled with the hydrated CPP freeze-dried composition at 24h, taking out, and pressing an aluminum-plastic combined cover to obtain 2g of the hydrated CPP freeze-dried composition with the specification.
2. Evaluation of the Properties of the hydrated Freeze-dried composition
1) Appearance of the product
In a freeze-drying box, the CPP freeze-dried composition hydrated by pure water under normal pressure and slight negative pressure presents a uniform and full state in a penicillin bottle.
2) Physical and chemical properties
The moisture content, the CPP content, and the reconstitution time of the CPP lyophilized composition hydrated using pure water in a lyophilizer under normal pressure and under slight negative pressure were measured, and the results are shown in the following Table 7-1.
TABLE 7-1 physicochemical Properties of the hydrated CPP lyophilized composition
Figure BDA0001868970780000241
1The% moisture content is calculated relative to the weight of the lyophilized composition.
2The% moisture content is calculated as weight relative to CPP monohydrate.
From Table 7-1, it can be seen that 2g of the lyophilized composition was hydrated with pure water at normal pressure for at least 72 hours to achieve the desired moisture content, while the lyophilized composition was hydrated with pure water at a slight negative pressure for only 24 hours to achieve the desired moisture content.
Example 8 hydration of lyophilized compositions Using purified Water (100% RH relative humidity at room temperature)
1. Method step
The CPP lyophilized composition was obtained according to the methods and procedures of 1) to 3) of example 3.
Then hydrating according to the following method:
4) and opening an air inlet valve of the freeze-drying box to enable sterile air to enter the freeze-drying box, relieving the vacuum state and closing the air inlet valve. And opening the front door of the freeze-drying box, placing the steam-sterilized pure water in a sterile tray at the bottommost layer of the shelf, and locking the front door. And (4) respectively plugging the penicillin bottles filled with the hydrated CPP freeze-dried composition at 16h and 24h, taking out, and pressing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
Or 4') transferring the CPP lyophilized composition obtained above to a production lyophilization tank (model DG-2010BSCSIP/CIP, shanghai consortium vacuum technology limited). The freezer front door was opened and steam sterilized pure water (about 36L) was placed at the bottom of the freezer (solution surface area about 2.5 m)2) And locking the front door. The shelf temperature was set at 25 ℃. The chamber of the freeze-drying box is vacuumized, when the pressure is about 60kPa, the vacuumizing is stopped, the septum valve is closed, and the hydration is started. And (5) plugging the penicillin bottle filled with the hydrated CPP freeze-dried composition at 15h, taking out, and pressing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
2. Evaluation of the Properties of the hydrated Freeze-dried composition
1) Appearance of the product
The CPP lyophilized composition hydrated with pure water in the lyophilization chamber under normal pressure and slight negative pressure is in a uniform and full state in the penicillin bottle.
2) Physical and chemical properties
The moisture content, the CPP content, and the reconstitution time of the CPP lyophilized composition hydrated using pure water in a lyophilization chamber under normal pressure and under slight negative pressure were measured, and the results are shown in the following table 8-1.
TABLE 8-1 physicochemical Properties of the hydrated CPP lyophilized composition
Figure BDA0001868970780000251
1The% moisture content is calculated relative to the weight of the lyophilized composition.
2The% moisture content is calculated as weight relative to CPP monohydrate.
As can be seen from Table 8-1, the CPP lyophilized composition which was not subjected to pure water hydration at normal pressure had a moisture content of 1.9%, was unstable, and had a reconstitution time of 2.08min, whereas the CPP lyophilized composition which was subjected to pure water hydration at normal pressure in the lyophilization chamber had a moisture content, a CPP content, and a reconstitution time which were satisfactory. In addition, the CPP lyophilized compositions hydrated for 16h and 24h with pure water were good in stability when left in an environment of 45 ℃ for 2 weeks. Therefore, the CPP freeze-dried composition with greatly improved stability can be obtained by the hydration method of the invention.
Under the micro negative pressure, the water content of the CPP freeze-dried composition which is not hydrated by pure water is 2.9 percent, and the water content and the CPP content of the CPP freeze-dried composition which is hydrated by pure water meet the requirements. In addition, the CPP freeze-dried composition which is hydrated for 15h by using pure water under the micro-negative pressure has good stability when placed in an environment of 40 ℃/75% RH for 1 month. Therefore, the CPP freeze-dried composition with greatly improved stability can be obtained by the hydration method of the invention.
Example 9 hydration of lyophilized compositions with sodium chloride solution at 70% saturation under slightly negative pressure
1. Method step
The CPP lyophilized composition was obtained in a lyophilization chamber (model LYO-0.5, manufactured by Shanghai Tokko technologies Co., Ltd.) according to the methods and procedures of 1) -3) of example 3.
Then hydrating according to the following method:
4) and opening an air inlet valve of the freeze-drying box to enable sterile air to enter the freeze-drying box, relieving the vacuum state and closing the air inlet valve. The freeze-drying box front door is opened, the steam sterilized sodium chloride solution with 70% saturation is placed in the sterile tray at the bottom layer of the shelf, and the front door is locked. And vacuumizing the front chamber of the freeze-drying box at room temperature, stopping vacuumizing when the pressure is about 60kPa, closing a septum valve, and starting hydration timing. And (5) plugging the penicillin bottle filled with the hydrated CPP freeze-dried composition at 15h, taking out, and pressing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
2. Evaluation of the Properties of the hydrated Freeze-dried composition
1) Appearance of the product
In the freeze-drying box, 500mg of CPP freeze-dried composition of specification hydrated by using sodium chloride solution with 70% saturation under slight negative pressure is in a uniform and full state in a penicillin bottle.
2) Physical and chemical properties
The moisture content, CPP content and stability of a 500 mg-sized CPP lyophilized composition hydrated in a lyophilizer under a slight negative pressure using a sodium chloride solution of 70% saturation were measured and the results are shown in Table 9-1 below.
TABLE 9-1 physicochemical Properties of the hydrated CPP lyophilized composition
Figure BDA0001868970780000261
1The% moisture content is calculated relative to the weight of the lyophilized composition.
2The% moisture content is calculated as weight relative to CPP monohydrate.
As can be seen from Table 9-1, the CPP lyophilized composition has a moisture content of 2.9% without hydration, while the CPP lyophilized composition hydrated in the lyophilization chamber with a sodium chloride solution of 70% saturation has satisfactory moisture content, CPP content and stability. In addition, the CPP lyophilized composition hydrated for 15h in a micro-negative pressure in a freeze-drying box by using a sodium chloride solution with 70% saturation has good stability when placed in an environment of 40 ℃/75% RH for 1 month. Therefore, the CPP freeze-dried composition with greatly improved stability can be obtained by the hydration method of the invention.
Example 10 hydration of lyophilized compositions with 30% Glycerol solution under slightly negative pressure
1. Method step
The CPP lyophilized composition was obtained in a lyophilization chamber (model LYO-0.5, manufactured by Shanghai Tokko technologies Co., Ltd.) according to the methods and procedures of 1) -3) of example 3.
Then hydrating according to the following method:
4) and opening an air inlet valve of the freeze-drying box to enable sterile air to enter the freeze-drying box, relieving the vacuum state and closing the air inlet valve. The front door of the freeze-drying box was opened, and a steam-sterilized 30% glycerol solution was placed in a sterile tray at the lowermost layer of the shelf (tray surface area: 330 cm)2) And locking the front door. Vacuumizing the front chamber of the freeze-drying box at room temperature, stopping vacuumizing when the pressure is about 50kPa, closing a septum valve, and starting hydration timing. And (5) plugging the penicillin bottle filled with the hydrated CPP freeze-dried composition at the 8h, taking out, and pressing an aluminum-plastic combined cover to obtain the hydrated CPP freeze-dried composition with the specification of 500 mg.
2. Evaluation of the Properties of the hydrated Freeze-dried composition
1) Appearance of the product
In the freeze-drying box, 500mg specification CPP freeze-dried composition hydrated by 30% glycerol solution under slight negative pressure is in a uniform and full state in a penicillin bottle.
2) Physical and chemical properties
The moisture content of a 500 mg-sized CPP lyophilized composition hydrated in a lyophilizer using a 30% glycerol solution under a slight negative pressure is measured as shown in the following table 10-1.
TABLE 10-1 physicochemical Properties of the hydrated CPP lyophilized compositions
Figure BDA0001868970780000271
1The% moisture content is calculated relative to the weight of the lyophilized composition.
2The% moisture content is calculated as weight relative to CPP monohydrate.
As can be seen from Table 10-1, the water content of the CPP lyophilized composition which had not been hydrated was 2.0%, whereas the water content of the CPP lyophilized composition which had been hydrated in a freezer using a 30% glycerol solution under a slight negative pressure was satisfactory. Therefore, the CPP freeze-dried composition with greatly improved stability can be obtained by the hydration method of the invention.
Example 11 bulk Density (BD or ρ0)
BD of the sample to be tested (e.g., CPP bulk drug, hydrated CPP lyophilized composition) was measured using a graduated cylinder according to method I described in USP <616 >.
BD is calculated by:
BD(g/mL)＝W/V0
wherein the content of the first and second substances,
w is the theoretical weight, g; v0Is the apparent volume, mL.
V was calculated according to the following formula0：
V0(mL)＝πD2h/4
Wherein the content of the first and second substances,
d is the theoretical inner diameter, cm; h is height, cm.
Bulk density results are listed in table 11.
TABLE 11 bulk Density
Figure BDA0001868970780000281
Example 12 Tap Density (TD)
The TD of the test sample was measured by mechanically vibrating a graduated cylinder (TAP Density tester, Sotax TD2) containing the test sample according to method I described in USP <616 >.
The results of TD measurements are shown in Table 12.
TABLE 12 tap Density
Figure BDA0001868970780000282
Example 13 bone Density (. rho.)1)
Bone density, also known as true density, is measured at room temperature by means of a gas pycnometer (Micromeritics Accupys II 1340).
Bone density was calculated by the following formula:
ρ1(g/mL)＝W/V1
wherein the content of the first and second substances,
w is the sample weight to be tested (e.g., active ingredient CPP, hydrated CPP lyophilized composition), g;
V1the true volume, mL, of the sample to be tested is determined using a gas pycnometer.
The bone density results are listed in table 13.
TABLE 13 bone Density
Figure BDA0001868970780000291
Example 14 porosity
Porosity is according to the apparent volume (V) in the following formula0) And true volume (V)1) Or bulk density (. rho.)0) And bone density (ρ)1) And (3) calculating:
porosity (%) - (1-V)1/V0)×100％＝(1-ρ0/ρ1)×100％
The porosity results are listed in table 14.
TABLE 14 porosity
Figure BDA0001868970780000292
Example 15X-ray powder diffraction (XRD)
The appropriate amount of the sample to be tested (e.g., CPP, mannitol, hydrated CPP lyophilized composition as active ingredient) was weighed separately, XRD pattern was recorded by Bruker's D8 new diffractometer (Karlsruhe, West Germany) equipped with 2 theta compensation slits, using copper K α radiation
Figure BDA0001868970780000293
Pass through a parabolic filter with a diverging slit (0.5 deg.), an anti-diverging slit (0.5 deg.) and a receiving slit (1mm) at 40kV and 40 mA. The peak position accuracy of the diffractometer was corrected with corundum. Continuously scanning under the conditions of 2 theta angle range of 6-36 degrees, step length of 0.02 degrees and residence time of 1s to obtain XRD patternAnalysis of diffractograms was performed using MDI/JADE (version 6.0) diffractogram β -and delta-mannitol standard diffractograms are referenced from the cif file in Mercury software, code DMANTL07DMANTL10, respectively, XRD patterns are shown in FIG. 1.
FIG. 1 shows the superimposed XRD patterns of CPP monohydrate, hydrated CPP lyophilized composition (initial ingredients including CPP monohydrate and delta-mannitol), and anhydrous mannitol in two crystal forms. the hydrated CPP lyophilized composition shows characteristic peaks of delta-mannitol without β -mannitol (2 theta values of 9.7 DEG, without 16.8 DEG peak). furthermore, the hydrated CPP lyophilized composition also shows characteristic peaks of CPP monohydrate (2 theta values of 7.0 DEG, 10.9 DEG, 14.0 DEG, and 17.8 DEG).
Solutions containing only mannitol were lyophilized to obtain a mixture of β - (major) and δ - (minor) polymorphic mannitol however, when CPP was also present in the mannitol solution, only δ -mannitol was observed in the lyophilized sample.
According to the method described in the examples of the present invention, the crystalline form of the hydrated CPP lyophilized composition hydrated with pure water can be characterized by the characteristic peaks in XRD pattern of 20.4 °, 23.6, 23.7 and 25.2 ° 2 θ ± 0.2 ° 2 θ. According to the methods described in the examples of the present invention, the crystalline form of the hydrated CPP lyophilized composition hydrated with pure water can also or alternatively be characterized by characteristic peaks in XRD patterns of 20.4 °, 21.9 °, 22.1 °, 23.6 °, 23.7 °, 25.2 ° and 25.4 ° 2 θ ± 0.2 ° 2 θ. In other embodiments, a crystalline form of a hydrated CPP lyophilized composition that is hydrated with pure water according to the methods described in the examples of the present invention can be characterized by an XRD pattern substantially as shown in fig. 2. Crystalline forms of the hydrated CPP lyophilized composition hydrated with pure water according to the methods described in the examples of the present invention may also or alternatively be characterized by characteristic peaks in the XRD pattern substantially as provided in Table 15 (+ -0.2 ° 2 θ) below.
TABLE 15 XRD of CPP lyophilized compositions hydrated with pure water
Figure BDA0001868970780000311
According to the method described in the examples of the present invention, the crystalline form of the hydrated CPP lyophilized composition hydrated with sodium chloride solution can be characterized by the characteristic peaks in XRD pattern of 20.4 °, 21.9, 23.6 and 23.72 θ ± 0.2 ° 2 θ. The crystalline form of the hydrated CPP lyophilized composition hydrated with sodium chloride solution according to the method described in the examples of the present invention can also or alternatively be characterized by characteristic peaks in XRD pattern of 20.4 °, 21.9, 22.1, 23.6, 23.7 and 25.42 θ ± 0.2 ° 2 θ. In other embodiments, a crystalline form of a hydrated CPP lyophilized composition hydrated with a sodium chloride solution according to the methods described in embodiments of the present invention can be characterized by an XRD pattern substantially as shown in fig. 3. Crystalline forms of the hydrated CPP lyophilized composition hydrated with sodium chloride solution according to the methods described in the examples of the present invention may also or alternatively be characterized by characteristic peaks in the XRD pattern substantially as provided in Table 16 (+ -0.2 ° 2 θ) below.
TABLE 16 XRD of CPP lyophilized compositions hydrated with sodium chloride solution
Figure BDA0001868970780000321
Figure BDA0001868970780000331
According to the method described in the embodiment of the invention, the crystal form of the hydrated CPP freeze-dried composition hydrated by using the glycerol solution can be characterized by the characteristic peaks of 20.4, 23.6, 23.7 and 25.22 theta +/-0.2 degrees 2 theta in an XRD pattern. The hydrated CPP lyophilized composition crystalline form hydrated with glycerol solution according to the methods described in the examples of the present invention can also or alternatively be characterized by characteristic peaks in XRD pattern of 20.4, 21.9, 22.1, 23.6, 23.7, 25.2 and 25.32 theta ± 0.2 ° 2 theta. In other embodiments, a crystalline form of a hydrated CPP lyophilized composition hydrated with a glycerol solution according to the methods described in embodiments of the present invention can be characterized by an XRD pattern substantially as shown in fig. 4. According to the methods described in the examples of the present invention, crystalline forms of the hydrated CPP lyophilized composition hydrated with a glycerol solution can be characterized by the characteristic peaks in the XRD pattern substantially as provided in Table 17 (+ -0.2 ° 2 θ) below.
TABLE 17 XRD of CPP lyophilized compositions hydrated with glycerol solution
Figure BDA0001868970780000332
Figure BDA0001868970780000341
EXAMPLE 16 reconstitution time
25ml of 0.9% sodium chloride solution is quickly added into a penicillin bottle filled with a sample to be tested (500mg of the hydrated CPP freeze-dried composition with the specification), or 100ml of 0.9% sodium chloride solution is quickly added into a penicillin bottle filled with a sample to be tested (2g of the hydrated CPP freeze-dried composition with the specification), and then the penicillin bottle is placed on a rotary oscillator (Cyclotron HY-5, Shanghai Suhao science and technology Co., Ltd.) to be oscillated at 250rpm at room temperature until the sample is completely dissolved. The reconstitution time is recorded in table 18.
TABLE 18 reconstitution time
Figure BDA0001868970780000342
Example 17 Particle Size Distribution (PSD)
The hydrated CPP lyophilized composition is gently stirred to a flowable powder using a weighing spoon, and then 1-2g of the sample to be tested is taken onto a sample tray. The test methods and parameters were as follows:
Figure BDA0001868970780000351
it will be appreciated by those of ordinary skill in the art that the conventional method of defining the distribution width is to introduce three values on the X-axis, i.e., D10, D50, and D90 are conventional methods of defining the distribution width. As used herein, the term "D50" refers to the median particle diameter, where the particle diameter of half of the particles in a population is below this value. As used herein, the term "D90" means that the particle size of 90% of the particles in the population is below this value. As used herein, the term "D10" means that the particle size of 10% of the particles in the population is below this value. The PSD results are listed in Table 19.
TABLE 19 particle size distribution
Figure BDA0001868970780000352
Example 18 stability in use
Samples to be tested (such as active ingredient CPP, hydrated CPP lyophilized composition) were reconstituted to 20mg/mL using 0.9% sodium chloride injection and then assayed for content and impurities at Room Temperature (RT) and refrigerated storage (2-8 deg.C) respectively.
The impurity determination method is as follows:
Figure BDA0001868970780000361
the content determination method comprises the following steps:
Figure BDA0001868970780000362
Figure BDA0001868970780000371
the in-use stability results are listed in table 20.
TABLE 20 stability in use
Figure BDA0001868970780000372
Example 19 stability
Samples to be tested (e.g. active ingredient CPP, hydrated CPP lyophilized composition) were placed in a 45 ℃ oven and sampled after 1 week and 2 weeks, respectively, to determine CPP content, and the storage stability results are shown in table 21.
TABLE 21 stability
Figure BDA0001868970780000381
While the invention has been illustrated and described with reference to exemplary embodiments, the invention is not intended to be limited to the details shown. Since various modifications and substitutions may be made without departing in any way from the spirit of the present invention, it is intended that all such modifications and equivalents of the invention as come within the spirit and scope of the invention as defined by the following claims be interpreted using the full breadth to which they are entitled using routine experimentation.

Claims (33)

1. A method of preparing a hydrated lyophilized cyclophosphamide composition, comprising:
(a) providing an aqueous solution containing cyclophosphamide;
(b) freeze-drying the aqueous solution to obtain a lyophilized composition; and
(c) hydrating the lyophilized composition with liquid water, thereby obtaining a hydrated cyclophosphamide lyophilized composition.
2. The method of claim 1, wherein the moisture content of the lyophilized composition obtained in step (b) is not higher than about 5.5% relative to the weight of cyclophosphamide.
3. The method of claim 1, wherein the liquid water is in the form of an aqueous solution comprising one or more selected from the group consisting of strong acids, strong bases, glycerol, inorganic salts, and pharmaceutically acceptable excipients.
4. The process of claim 3 wherein the aqueous solution is a 70% saturated sodium chloride solution and the relative humidity in the hydrating step (c) is about 70 to about 95%.
5. The method of claim 4, wherein the XRD pattern of the hydrated cyclophosphamide lyophilized composition has characteristic peaks at 20.4 °, 23.6 °, 23.7 ° and 25.2 ° 2 θ ± 0.22 θ.
6. A lyophilized composition comprising at least about 99% cyclophosphamide after 3 weeks at 45 ℃.
7. A lyophilized composition comprising, relative to the weight of the composition, at least about 99% cyclophosphamide after 1 month at 40 ℃ and 75% relative humidity.
8. The composition of claim 7, wherein the reconstitution time of the composition in a diluent is 2 minutes or less.
9. A composition comprising hydrated lyophilized cyclophosphamide, wherein the moisture content in the composition is not higher than about 5.5% relative to the weight of the composition.
10. An injectable composition comprising, relative to the weight of the composition, at least about 99% cyclophosphamide after 3 weeks at 45 ℃.
11. An injectable composition comprising, relative to the weight of the composition, at least about 99% cyclophosphamide after 1 month of standing at 40 ℃ and 75% relative humidity.
12. The composition of claim 11, wherein the reconstitution time of the composition in a diluent is 2 minutes or less.
13. A composition for injection comprising at least about 98% cyclophosphamide and less than 0.7% cyclophosphamide impurity B as determined by HPLC after reconstitution in a diluent and storage at room temperature for up to 6 hours.
14. A composition for injection comprising less than 0.1% cyclophosphamide impurity B as determined by HPLC after storage at 45 ℃ for up to 7 days.
15. A composition for injection comprising less than 0.1% cyclophosphamide impurity a as determined by HPLC after storage at 45 ℃ for up to 7 days.
16. A sterile injectable preparation prepared by mixing a lyophilized composition with a diluent, wherein the hydrated cyclophosphamide contained in the lyophilized composition has a moisture content not higher than about 5.5% relative to the weight of the composition.
17. A sterile injectable formulation prepared by mixing a lyophilized composition and a diluent, wherein the lyophilized composition comprises hydrated cyclophosphamide, and wherein the formulation comprises at least about 98% cyclophosphamide and 0.7% or less cyclophosphamide impurity B as determined by HPLC when stored at room temperature for up to 6 hours after reconstitution of the formulation.
18. A composition comprising lyophilized cyclophosphamide, wherein the XRD pattern of cyclophosphamide has characteristic peaks at 20.4 °, 23.6 °, 23.7 ° and 25.2 ° 2 Θ ± 0.22 Θ.
19. The composition of claim 18, further comprising a detectable amount of a material selected from the group consisting of strong acids, strong bases, glycerin, inorganic salts, and pharmaceutically acceptable excipients.
20. An injectable composition comprising lyophilized cyclophosphamide, wherein the XRD pattern of cyclophosphamide has characteristic peaks at 20.4 °, 23.6 °, 23.7 ° and 25.2 ° 2 Θ ± 0.22 Θ.
21. The composition of claim 20, further comprising a detectable amount of a material selected from the group consisting of strong acids, strong bases, glycerin, inorganic salts, and pharmaceutically acceptable excipients.
22. A composition for injection comprising at least about 99% cyclophosphamide relative to the weight of the composition after 3 months at 40 ℃ and 75% relative humidity.
23. The composition of claim 22, wherein the reconstitution time of the composition in a diluent is 2 minutes or less.
24. A lyophilized composition comprising cyclophosphamide, wherein the bulk density of the composition is about 0.0600g/mL or less.
25. A lyophilized composition comprising cyclophosphamide, wherein the tap density of the composition is about 0.300g/mL or less.
26. A lyophilized composition comprising cyclophosphamide, wherein the composition has a bone density of about 1.4700g/mL or greater.
27. A lyophilized composition comprising cyclophosphamide, wherein the porosity of the composition is above 96%.
28. A lyophilized composition comprising cyclophosphamide, wherein the particle size distribution of the composition characterized by a D50 value is less than 11.0 μ ι η.
29. An injectable composition comprising cyclophosphamide, wherein the particle size distribution of the composition, characterized by a D50 value, is less than 11.0 μ ι η.
30. A lyophilized composition comprising cyclophosphamide, wherein the particle size distribution of the composition characterized by a D90 value is less than 36.0 μ ι η.
31. The composition of claim 30, wherein the particle size distribution of the composition, characterized by a D90 value, is less than 29.0 μ ι η.
32. An injectable composition comprising cyclophosphamide, wherein the particle size distribution of the composition, characterized by a D90 value, is less than 36.0 μ ι η.
33. An injectable composition comprising cyclophosphamide, wherein the particle size distribution of the composition, characterized by a D90 value, is less than 29.0 μ ι η.
CN201811367499.4A 2018-08-03 2018-11-16 Method for hydrating cyclophosphamide freeze-dried composition and product thereof Pending CN111195235A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201811367499.4A CN111195235A (en) 2018-11-16 2018-11-16 Method for hydrating cyclophosphamide freeze-dried composition and product thereof
US17/265,678 US20220133754A1 (en) 2018-08-03 2019-08-05 Method for hydrating lyophilized cyclophosphamide composition and product thereof
EP19844577.7A EP3831366A4 (en) 2018-08-03 2019-08-05 Method for hydrating lyophilized cyclophosphamide composition and product thereof
PCT/CN2019/099251 WO2020025069A1 (en) 2018-08-03 2019-08-05 Method for hydrating lyophilized cyclophosphamide composition and product thereof
CN201980051898.6A CN112533591A (en) 2018-08-03 2019-08-05 Method for hydrating cyclophosphamide freeze-dried composition and product thereof
PCT/IB2019/059802 WO2020100088A1 (en) 2018-11-16 2019-11-14 A process for hydrating cyclophosphamide freeze-dried composition and product thereof
US16/684,038 US20200155579A1 (en) 2018-11-16 2019-11-14 Process for Hydrating Cyclophosphamide Freeze-Dried Composition and Product Thereof
IL283170A IL283170A (en) 2018-11-16 2021-05-13 A process for hydrating cyclophosphamide freeze-dried composition and product thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811367499.4A CN111195235A (en) 2018-11-16 2018-11-16 Method for hydrating cyclophosphamide freeze-dried composition and product thereof

Publications (1)

Publication Number Publication Date
CN111195235A true CN111195235A (en) 2020-05-26

Family

ID=70740899

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811367499.4A Pending CN111195235A (en) 2018-08-03 2018-11-16 Method for hydrating cyclophosphamide freeze-dried composition and product thereof

Country Status (1)

Country Link
CN (1) CN111195235A (en)

Similar Documents

Publication Publication Date Title
JP3503943B2 (en) Crystalline amifostine composition and method for its preparation and use
FI117924B (en) Methods for the preparation of crystalline amifostine compositions
JP6182262B2 (en) Stable water-soluble pharmaceutical composition containing anticancer agent
WO2010030598A2 (en) Pharmaceutical formulations comprising pemetrexed
MX2014014225A (en) Compositions comprising short-acting benzodiazepines.
JP2003530321A (en) Novel crystals of N- [4- [2- (2-amino-4,7-dihydro-4-oxo-3H-pyrrolo [2,3-d] pyrimidin-5-yl) ethyl] benzoyl] -L-glutamic acid Shape and manufacturing method thereof
ES2799512T3 (en) Amorphous form of an AKT inhibitor pyrimidinyl-cyclopentane compound, compositions and methods thereof
CA1056729A (en) Injectable amoxycillin composition
WO2016077406A1 (en) Carmustine pharmaceutical composition
JP6248189B2 (en) Arginine salt of stable anticancer agent and composition containing the same
ES2553639T3 (en) Method to purify rocuronium bromide
US20180256608A1 (en) Lyophilized Cyclophosphamide Composition and Methods of Preparation Thereof
US20120196834A1 (en) Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
CN111195235A (en) Method for hydrating cyclophosphamide freeze-dried composition and product thereof
CN112533591A (en) Method for hydrating cyclophosphamide freeze-dried composition and product thereof
EP2041130A1 (en) Novel hydrate form of moxifloxacin monohydrochloride
CN110787137A (en) Hydration method of cyclophosphamide freeze-dried composition and product thereof
WO2020100088A1 (en) A process for hydrating cyclophosphamide freeze-dried composition and product thereof
CN111821309B (en) Darunavir composition with improved dissolution rate
TW200820966A (en) Lyophilized formulation of 1-methylcarbapenem compounds
CN105343014A (en) Racemic 2-(alpha-hydroxy amyl) benzoate freeze-dried powder injection and preparation method thereof
EP3054924A1 (en) Stable pharmaceutical formulations of caspofungin
WO2004000323A1 (en) Medicinal cephem compound composition for injection
CN103435615B (en) Ganciclovir compound as well as preparation method and pharmaceutical composition thereof
WO2004050098A1 (en) Freeze-dried preparation of stabilized anthracycline compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: Room 205 and 207, 515 huanke Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201210

Applicant after: Shanghai xuantai Pharmaceutical Technology Co., Ltd

Address before: 201203 1st floor, building 3, 99 Haike Road, Pudong New Area, Shanghai

Applicant before: SINOTHERAPEUTICS Inc.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200526

WD01 Invention patent application deemed withdrawn after publication